20th KM, Hosur Road,Electronic City, Bengaluru Karnataka 560100

8028082808
www.biocon.com

ABOUT:
Biocon Limited, headquartered in Bangalore, India, was established in 1978 by
Kiran Mazumdar-Shaw. The company is a prominent player in the
biopharmaceutical sector and has a strong global presence, with its products
being distributed in approximately 120 countries, including the United States and
Europe. Biocon's core focus extends to manufacturing generic active
pharmaceutical ingredients (APIs), which are marketed internationally.

Additionally, the company is involved in the production of novel biologics,

biosimilar insulins, and antibodies. These products are available in India under
branded formulations, and Biocon's biosimilar offerings are distributed in various
forms, including bulk and formulation, in emerging markets. Biocon's versatility in
its product offerings demonstrates its commitment to addressing diverse
healthcare needs. Its reach into key markets around the world underscores its
significance in providing pharmaceutical solutions on a global scale.
HISTORY:
 Biocon was founded in 1978 with Rs.10,000 as the initial capital by a Kiran
Mazumdar who was born to Gujarati parents in Bangalore.
 In 1979 Biocon Became the first Indian company to manufacture and export
enzymes to the US and Europe.
 In 1989 Unilever acquired Biocon Biochemicals Ltd. in Ireland and merges it
with its subsidiary, Quest International; Biocon receives US funding for
proprietary technologies.
 In 1994 Biocon established Syngene International Pvt. Ltd. as a Custom
Research Company (CRC).
 During 1998 Unilever agrees to sell its shareholding in Biocon to the Indian
promoters. Biocon becomes an independent entity.
 In 2001 Biocon became the first Indian company to be approved by USFDA
for the manufacture of lovastatin; PlaFractor is granted a US 2001 and
worldwide patent.
 In 2003 Biocon becomes the first company worldwide to develop human
insulin on a Pichia expression system.
 During 2006 BIOMAb EGFR, first indigenously developed humanised
monoclonal antibody for head-and-neck cancer is launched and Dr. APJ
Abdul Kalam inaugurates India's Largest Biotech-Hub "Biocon Park"
 In 2008 Biocon acquires a 70% stake in German pharmaceutical company,
AxiCorp GmbH.
 During 2009 Syngene-Bristol Myers Squibb research facility is established in
Bengaluru.
 Later during 2009 Mylan announced strategic collaboration with Biocon to
Enter the Global Generic Biologics Market.
 In 2010 Biocon expanded to Malaysia, biopharmaceutical manufacturing
and R&D facility established in Iskandar Malaysia, Johor.
 In 2012 Abbott announces collaboration with Syngene to Open First
Nutrition R&D Center in India
 During 2013 Biocon launched biologic drug ALZUMAb to treat psoriasis.
 During 2014 Biocon launched the first biosimilar drug CANMAb to treat
breast cancer.
 In 2015 Biocon launched hepatitis-C drug in India under brand name
CIMIVIR-L.
 In 2016, Biocon Became the first Indian company to launch a biosimilar
Insulin Glargine pen in Japan.
 During 2016, Syngene set up Amgen R&D center in Bangalore.[23] In 2017,
Biocon's Insugen became the first locally manufactured biosimilar product
to be approved for sale by the Malaysian drug regulator. In 2017, USFDA
approves Mylan-Biocon's biosimilar for cancer drug Herceptin.
 During 2021 Biocon Biologics and Serum Institute of India formed a joint
agreement to commercialise vaccines, biological drugs, and antibody
therapies together.
 Another aspect of the deal involves Bicocon selling 15% of its biologics
subsidiary to Serum Institute of India, in return for Biocon gaining access to
100 million annual doses of vaccines for a 15-year period.
 During 2022, Biocon Biologics buys the biosimilar assets of Viatris, for $3.34
billion
SUBSIDARIES OF BIOCON:

Biocon R esearch Lim ited (BRL)

Biocon Biopharm aceuticals Pvt. Ltd.

N eoB iocon

Biocon -A xiCorp

Clinigene

Biofusion Biologics

Syngene International Pvt. Ltd.

Biocon Biologics

Biocon Biologics is Biocon's biosimilar subsidiary. In 2021 Biocon and Viatris

received approval to launch Semglee, an insulin glargine-yfgn injection, which is
the first interchangble biosimilar for diabetes in the United States.

In 2021, Biocon Biologics sold 15% of the subsidiary to Serum Institute of India for
a valuation of $4.9 billion, for which Biocon will receive access to 100 million
doses of vaccines per annum for 15 years. These vaccines will mainly be supplied
from Serum Institute's upcoming vaccine facility in Pune, and Biocon will also
have the commercialization rights of Serum Institute's vaccine portfolio, which
includes the COVID-19 vaccine, for the international markets. In May 2022, Viatris
sold its biosimilars division to Biocon Biologies for a price of US$3.335 billion.
Syngene International Ltd
Established in 1993, Syngene International Limited is a contract research and
development organization (CDMO). In the CDMO space, Syngene primarily
focuses on research innovation and manufacturing services for their clients. The
company has four divisions: drug discovery services, dedicated research centres,
development devices and manufacturing. Syngene works with eight of the top 10
global pharma firms and, the company's clients include Amgen, Zoetis,
GlaxoSmithKline and Bristol Myers Squibb.

Syngene has been expanding its operations. Since 2020, he company has opened
an R&D centre in Hyderabad, is building an API manufacturing facility in
Mangalore, which is scheduled to be commissioned in 2022, and has expanded
their R&D facility in Bangalore.

Syngene also provides biologics CDMO services.In July 2022, Syngene signed a 10-
year agreement with Zoetis to manufacture the drug substance for Librela
(bedinvetmab), a first-in-class monoclonal antibody used for treating
osteoarthritis in dogs. SynVent is Syngene's drug discovery and development
platform for both small and large molecules. In September 2022, Biocon divested
5.4% of its shares in Syngene International.

Clinigene
Clinigene International Limited is a subsidiary on Syngene offering international
pharmaceutical majors Phase I-IV clinical trials and studies for novel/generic
molecules.[
BBPL
Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2003 as a joint
venture with the Cuban institute CIMAB to develop and market a range of MAbs
and cancer vaccines.
Biocon-AxiCorp
In 2008, Biocon acquired a majority stake of 70% in AxiCorp GmbH, a German
pharmaceutical marketing company.
NeoBiocon:
Incorporated in January 2008, NeoBiocon FZ LLC is a research and marketing
pharmaceutical company based in UAE

PRODUCTS OF BIOCON:

BIOSIMILARS BRANDED
FORMULATION

NOVEL
GENERICS
BIOLOGICS

Products of biocon are classified into 4 broad spectrums such as genrics,

biosimilars, branded formulation and novel biologics. These each spectrum
further divides broad and large into deeper pharmaceuticals analogies.

They deal with medications ranging from Anti-Cancer/Oncology, Rh-insulin,

Multiple Sclerosis, Immunosuppressant, Anti-Diabetics, Cardiology, Nephrology.

https://www.1mg.com/manufacturer/biocon-55680
The above link enables us to have vision of marketed drugs from biocon.
 BIOCON MANUFACTURING PLANTS IN INDIA:

These are the manufacturing plants of Biocon in India:

BIOCON CAMPUS, BANGALORE:

ADDRESS: 20th KM, Hosur Rd, Electronic City, Bengaluru, Karnataka 560100
080 2808 2808

BIOCON PARK BANGALORE:

ADDRESS: 131, Bommasandra Jigani Link Rd, Bommasandra Industrial Area,
Bengaluru, Bommasandra, Karnataka 560099

BIOCON LIMITED, HYDERABAD

ADDRESS: Plot No 213, 214 & 215, Phase II, IDA Pashamylaram, Sanga Reddy
District, Patancheruvu, Telangana 502307

BIOCON LIMITED, VISHAKHAPATNAM:

ADDRESS: Unit, Plot No.95, Ramky Pharma City, SEZ Jawaharlal Nehru Pharma
City, Parawada (M) Visakhapatnam, Andhra Pradesh, 531021

And another unit at M34W+64F, Donkada, Andhra Pradesh 531021

BIOCON UNIT IN MALAYSIA:

Kawasan Perindustrian SILC, 1, Jln Bioteknologi 1, 79200 Iskandar Puteri, Johor,

Malaysia
ECONOMIC PROSPECTS OF BIOCON IN FY2023:

Net income 787 crore (US$99 million) (FY2023)

Total assets 52,044 crore (US$6.5 billion) (2023)

Operating income 2,888 crore (US$360 million) (FY2023)

Total equity 22,489 crore (US$2.8 billion) (2023)

Number of employees 16,545 (Mar 2023)

In the financial year of 2023, the company achieved noteworthy financial results,
reporting a net income of 787 crore (US$99 million), highlighting its strong
profitability. Simultaneously, the company's operating income for the same fiscal
year reached 2,888 crore (US$360 million), demonstrating its robust operational
performance.

When looking at the broader financial picture, as of 2023, the company boasted a
substantial total asset base of 52,044 crore (US$6.5 billion), underscoring its
significant scale and assets under management.

Furthermore, its total equity stood at an impressive 22,489 crore (US$2.8 billion),
affirming its solid financial footing. Beyond the numbers, the company's
workforce also deserves mention, as it employed a dedicated team of 16,545
individuals as of March 2023, showcasing its commitment to human capital
R&D CENTRE:

Location:
20th KM, Hosur Road,Electronic City, Bengaluru Karnataka 560100

R&D is an integral part of their business, and they are committed to investing in it
across all business segments to drive future growth. With four decades of
experience in fermentation technology, biotransformation, and bio-catalysis,
Biocon, under it’s leadership, stands as a frontrunner in green chemistry.

Biocon's state-of-the-art R&D facilities in Bangalore have a sharp focus on diverse

products within the realm of Generics, supporting both API and Formulations
businesses. R&D team consists of over 300 highly qualified scientists and
postgraduates from various science and engineering disciplines.

They harness the company's biotechnology and chemistry capabilities to tackle

complex molecules and high-end product and process characterizations. The
development team receives vital support from 50+ process engineers, aiding in
scaling up from laboratory to pilot and commercial scales, with a keen eye on
patent accessibility.

Furthermore, they ensures the presence of a dedicated pharma covigilance team

and clinical team to provide robust support to the development efforts.

They have Upstream facility and pilot plant area, Downstream facility
Synthetic chemistry valves, isolators, Solid and solution phase peptide synthesis
with purification facility.

OPERATIONS ACROSS THE GLOBE:

Biocon’s commercial footprint for biosimilars straddles the developed and

developing countries by leveraging strong regional and global partnerships. Our
biosimilars are currently benefiting patients in over 100 countries.
Through partnership with Viatris, Biocon Biologics has been able to access all the
key developed markets with multiple products across therapy areas, creating a
strong track record.

Market shares garnered by our products have meaningfully contributed to the

growing biosimilar penetration in the U.S. We have pursued select European
countries thus far as a part of our Viatris collaboration.

In other developed markets of Canada, Australia and Japan, products continue to

see strong demand. For instance, we have one of the leading biosimilar
Trastuzumab in Canada and Australia.

It’s presence in emerging markets has been fortified through our organically
developed B2B business and Viatris’ emerging markets business. Our B2B
business has increased its breadth by entering new countries through regional
partnerships and addition of new products following approval in developed
markets.

In addition to the products developed in collaboration with Viatris, we have been

commercializing recombinant human insulin (rHI) through our B2B platform.
Biocon Biologics has been investing to build its direct commercial footprint in
emerging markets, allowing us to capture higher value from the products sold in
the region. We have added field force in the UAE and Saudi Arabia to augment
commercialization efforts for our biosimilars in the region, enabling us to get
closer to the patients and customers.

The acquisition of Viatris’ global biosimilars business will enable Biocon Biologics
to have a direct commercial presence in the advanced markets of U.S., Canada,
EU, Australia and New Zealand, in addition to several emerging markets. It will
take us closer to patients, payors and healthcare systems and strengthen our
position as a global biosimilars player.